Lessons Learned From Option B+ in the Evolution Toward "Test and Start" From Malawi, Cameroon, and the United Republic of Tanzania.

J Acquir Immune Defic Syndr

*Malawi Ministry of Health HIV and AIDS Department, Ministry of Health, Lilongwe, Malawi; †Centers for Disease Control and Prevention, Lilongwe, Malawi; ‡Dignitas International, Zomba, Malawi; §College of Medicine, University of Malawi, Blantyre, Malawi; ¶United Nations Children's Fund (UNICEF), Abuja, Nigeria; ‖Management Sciences for Health, Lilongwe, Malawi; #Joint United Nations Programme on HIV/AIDS (UNAIDS), Lilongwe, Malawi; **United States Agency for International Development (USAID), Lilongwe, Malawi; ††Department of Monitoring, Evaluation and Research, Lighthouse Clinic, Lilongwe, Malawi; ‡‡The International Union Against Tuberculosis and Lung Disease, Center for Operational Research, Paris, France; §§Ministry of Health, Community Development, Gender, Elderly and Children, Dar es Salaam, United Republic of Tanzania; ¶¶Cameroon Baptist Convention Health Services, Bamenda, Cameroon; and ‖‖International Training and Education Center for Health (I-TECH), University of Washington, Seattle, WA.

Published: May 2017

The acceleration of prevention of mother-to-child transmission (PMTCT) activities, coupled with the rollout of 2010 World Health Organization (WHO) guidelines, led to important discussions and innovations at global and country levels. One paradigm-shifting innovation was Option B+ in Malawi. It was later included in WHO guidelines and eventually adopted by all 22 Global Plan priority countries. This article presents Malawi's experience with designing and implementing Option B+ and provides complementary narratives from Cameroon and Tanzania. Malawi's HIV program started in 2002, but by 2009, the PMTCT program was lagging far behind the antiretroviral therapy (ART) program because of numerous health system challenges. When WHO recommended Option A and Option B for PMTCT in 2010, it was clear that Malawi's HIV program would not be able to successfully implement either option without increasing existing barriers to PMTCT services and potentially decreasing women's access to care. Subsequent stakeholder discussions led to the development of Option B+. Operationalizing Option B+ required several critical considerations, including the complete integration of ART and PMTCT programs, systematic reduction of barriers to facilitate doubling the number of ART sites in less than a year, building consensus with stakeholders, and securing additional resources for the new program. During the planning and implementation process, several lessons were learned which are considerations for countries transitioning to "treat-all": Comprehensive change requires effective government leadership and coordination; national clinical guidelines must accommodate health system limitations; ART services and commodities should be decentralized within facilities; the general public should be well informed about major changes in the national HIV program; and patients should be educated on clinic processes to improve program monitoring.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415299PMC
http://dx.doi.org/10.1097/QAI.0000000000001326DOI Listing

Publication Analysis

Top Keywords

hiv program
12
lessons learned
8
option
8
malawi's hiv
8
health system
8
program
7
pmtct
5
learned option
4
option evolution
4
evolution "test
4

Similar Publications

The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4 T cell count.

View Article and Find Full Text PDF

Background: We report findings from an experimental medicine study of rationally designed prefusion stabilised native-like HIV envelope glycoprotein (Env) immunogens, representative of global circulating strains, delivered by sequential intramuscular injection.

Methods: Healthy adult volunteers were enrolled into one of five groups (A to E) each receiving a different schedule of one of two consensus Env immunogens (ConM SOSIP, ConS UFO, either unmodified or stabilised by chemical cross-linking, followed by a boost with two mosaic Env immunogens (Mos3.1 and Mos3.

View Article and Find Full Text PDF

Agreement analysis and associated factors of SARC-F and SARC-CALF in screening of risk sarcopenia in people living with human immunodeficiency virus.

Clinics (Sao Paulo)

January 2025

Posgraduate Program in Food, Nutrition and Health, Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados, Mato Grosso do Sul, Brazil. Electronic address:

Introduction: People Living with Human Immunodeficiency Virus (PLHIV) appear to be at a higher risk of developing sarcopenia. Various factors seem to influence the risk of sarcopenia, and its prevalence may differ depending on the screening tool used. This study aimed to (i) Screen the risk of sarcopenia in PLHIV using the SARC-F and SARCCalf and identify associated factors; (ii) Analyze the agreement between the instruments in PLHIV.

View Article and Find Full Text PDF

Background: Adherence to HIV treatment regimens involves the consistent and correct intake of all prescribed medications. The implementation of antiretroviral therapy (ART) program has significantly reduced mortality among adolescents living with HIV. However, adherence to ART is lower among adolescents compared to other sub-populations and even lower in sub-Saharan Africa.

View Article and Find Full Text PDF

Background: Preterm birth (PTB) is a leading cause of neonatal mortality, particularly in sub-Saharan Africa where 40% of global neonatal deaths occur. We identified and combined demographic, clinical, and psychosocial correlates of PTB among Kenyan women to develop a risk score.

Methods: We used data from a prospective study enrolling HIV-negative women from 20 antenatal clinics in Western Kenya (NCT03070600).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!